SCHEMBL9892864

SCHEMBL9892864

CCc1sc(NC(=O)[C@@H]2CCN2C(=O)OC(C)(C)C)nc1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.54
ALDH1A1 P00352 3/20 0.53
HSD17B10 Q99714 2/20 0.53
HPGD P15428 1/20 0.53
TSHR P16473 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.50
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
USP30 Q70CQ3 2/20 0.46
RORC P51449 1/20 0.45
ADORA2A P29274 2/20 0.44
ADORA1 P30542 2/20 0.44
NPC1 O15118 1/20 0.43
TRPV4 Q9HBA0 4/20 0.43
LMNA P02545 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CKS1B P61024 1/20 0.41
SKP1 P63208 1/20 0.41
SKP2 Q13309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3710631 0.94 L3MBTL1 (0.54) MAPTALDH1A1HSD17B10HPGDTSHR
SCHEMBL13257813 0.94 L3MBTL1 (0.54) MAPTALDH1A1HSD17B10HPGDTSHR
SCHEMBL9107659 0.86 MAPT (0.52) MAPTALDH1A1HSD17B10HPGDTSHR
SCHEMBL20458149 0.83 ALDH1A1 (0.46) MAPTALDH1A1HSD17B10HPGDTSHR
SCHEMBL9892850 0.80 CNR2 (0.56) MAPTALDH1A1HSD17B10HPGDTSHR
SCHEMBL2490286 0.79 L3MBTL1 (0.56) MAPTALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL2317236 0.79 L3MBTL1 (0.56) MAPTALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL20370279 0.79 USP30 (0.70) L3MBTL1MEN1KMT2AUSP30ADORA2A
SCHEMBL9892928 0.79 SMN1; SMN2 (0.56) MAPTALDH1A1HSD17B10L3MBTL1MEN1
SCHEMBL9892916 0.79 TP53 (0.60) MAPTHSD17B10L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443107-B1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2018-08-08 EP disclosed
US-8383615-B2 Azetidine 2-carboxamide derivatives which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-26 US disclosed
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-07 US disclosed
WO-2010147791-A1 AZETIDINE 2 -CARBOXAMIDE DERIVATIVES WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142666-A1 Azetidine 2-Carboxamide Derivatives Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 MAPT 4331/4885ALDH1A1 1724/4885HSD17B10 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.